+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hodgkin's Lymphoma - Pipeline Insight, 2021

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • September 2021
  • Region: Global
  • DelveInsight
  • ID: 5240452
This “Hodgkin's lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Hodgkin's lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Hodgkin's lymphoma Understanding

Hodgkin's lymphoma: Overview


Hodgkin's lymphoma, formerly known as Hodgkin's disease, is a cancer of the lymphatic system. It is one of the most curable forms of cancer. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of Reed-Sternberg cells (named for the scientists who first identified them). The most common symptom of Hodgkin's lymphoma is swelling of the lymph nodes, which causes a lump to form under the skin. This lump usually isn't painful. It may form in one or more of the areas including on the side of the neck, in the armpit, and/or around the groin. A biopsy of an enlarged lymph node is done to diagnose Hodgkin's lymphoma along with medical history and physical examination. The treatment of Hodgkin lymphoma depends on the type and stage of Hodgkin lymphoma and includes chemotherapy and radiotherapy.

"Hodgkin's lymphoma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hodgkin's lymphoma pipeline landscape is provided which includes the disease overview and Hodgkin's lymphoma treatment guidelines. The assessment part of the report embraces, in depth Hodgkin's lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hodgkin's lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hodgkin's lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Hodgkin's lymphoma.

Hodgkin's lymphoma Emerging Drugs Chapters


This segment of the Hodgkin's lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hodgkin's lymphoma Emerging Drugs


AFM-13: Affimed


AFM-13 is a NK cell-engaging, tetravalent bispecific-antibody (TandAb). It consists of two parts. The first contains two binding sites for CD30, found on the cancerous cells. The second contains two binding sites for CD16A, the receptor to activate the NK cell. The drug is in Phase II clinical studies for the treatment of relapsed or refractory Hodgkin lymphoma.

Camidanlumab tesirine: ACD Therapeutics


Camidanlumab tesirine (Cami, formerly ADCT-301) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25, conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. The drug is in Phase II clinical studies for the treatment of relapsed or refractory Hodgkin lymphoma and a Phase Ib clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.

Hodgkin's lymphoma: Therapeutic Assessment


This segment of the report provides insights about the different Hodgkin's lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hodgkin's lymphoma


There are approx. 14+ key companies which are developing the therapies for Hodgkin's lymphoma. The companies which have their Hodgkin's lymphoma drug candidates in the most advanced stage, i.e. Phase II include, Affimed.

Phases


This report covers around 14+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Hodgkin's lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hodgkin's lymphoma: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hodgkin's lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hodgkin's lymphoma drugs.

Hodgkin's lymphoma Report Insights

  • Hodgkin's lymphoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Hodgkin's lymphoma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Hodgkin's lymphoma drugs?
  • How many Hodgkin's lymphoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hodgkin's lymphoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hodgkin's lymphoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hodgkin's lymphoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Pfizer
  • Affimed
  • Bio-Path Holdings
  • 4SC
  • CStone Pharmaceuticals
  • ACD Therapeutics
  • Tessa Therapeutics
  • Chia Tai Tianqing Pharmaceutical Group

Key Products

  • Avelumab
  • AFM-13
  • BP 1002 Bio-Path Holdings
  • Resminostat
  • CS1001
  • Camidanlumab tesirine
  • TT-11
  • TQB2450


This product will be delivered within 2 business days.

Table of Contents

Introduction

Executive Summary

Hodgkin’s lymphoma: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Hodgkin’s lymphoma - Analytical Perspective

Late Stage Products (Phase III)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

AFM-13: Affimed
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

BP 1002: Bio-Path Holdings
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical/Discovery Stage Products
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Hodgkin’s lymphoma Key Companies

Hodgkin’s lymphoma Key Products

Hodgkin’s lymphoma- Unmet Needs

Hodgkin’s lymphoma- Market Drivers and Barriers

Hodgkin’s lymphoma- Future Perspectives and Conclusion

Hodgkin’s lymphoma Analyst Views

AppendixList of Tables
Table 1 Total Products for Hodgkin's lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Hodgkin’s lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pfizer
  • Affimed
  • Bio-Path Holdings
  • 4SC
  • CStone Pharmaceuticals
  • ACD Therapeutics
  • Tessa Therapeutics
  • Chia Tai Tianqing Pharmaceutical Group